Actavis: FDA OKs LILETTA To Prevent Pregnancy For Up To 3 Years - Quick Facts

(RTTNews) - Actavis plc (ACT), a global specialty pharmaceutical company, and Medicines360, a nonprofit women's health pharmaceutical company, today announced the approval of LILETTA by the U.S. Food and Drug Administration or FDA for use by women to prevent pregnancy for up to three years. LILETTA is placed in the uterus by a healthcare professional and works by continuously releasing levonorgestrel, a progestin, to prevent pregnancy.

Actavis and Medicines360's groundbreaking partnership would allow women, regardless of income and insurance coverage, to access this new and effective contraceptive option. Through the collaboration, LILETTA would be available in the U.S. commercially as well as at a lower cost to public health clinics enrolled in the 340B Drug Pricing Program.

Actavis and Medicines360 anticipate that LILETTA would be available for use in the U.S. by the second quarter of 2015.